Novartis Animal Health has launched Zolvix, billed as the first truly novel anthelmintic class for livestock to be launched in more than 25 years, together with a new drenching system designed to make drenching faster, easier and more accurate.
Zolvix contains a new active ingredient, monepantel, which kills all key sheep gastro-intestinal nematodes (roundworms), including those resistant to the existing treatments.
According to the company, the development of this new drench follows the persistent challenge from worms that have developed resistance to the three other classes of drench - white (benzimidazole or 1-BZ), yellow (levamisole or 2-LV) and clear (macrocyclic lactone or 3-ML) and combinations of these. Zolvix has a unique mode of action and so forms a fourth generation of anthelmintic, which will be known as the 4- AD, or orange drench class
Novartis Animal Health has prioritised the UK and Ireland as key launch countries for Zolvix to provide their sheep farmers with an answer to the pressing challenge of increasing anthelmintic resistance.
Lesley Stubbings, an Independent sheep consultant and Sustainable Control of Parasites in Sheep (SCOPS) panel member, said: "Resistance has become an ever increasing threat since the last new anthelmintic group was introduced to the UK market more than 25 years ago. Zolvix offers farmers a valuable opportunity to maintain good worm control and prolong the effective life of the existing products. Following the SCOPS guidelines to carefully integrate Zolvix into worm control strategies, before the other groups fail, will allow our sheep industry to reap the full benefits of this new novel group."
A study carried out by Novartis in conjunction with the Hopkirk Research Institute showed that Zolvix treated sheep gained 33.5%, or 2.8 kg deadweight, more than sheep treated with a drench to which they were resistant.
Novartis Animal Health Brand Manager Simon Harris said: "Parasite resistance is a growing problem that decreases the productivity of sheep of all ages. Many veterinarians and farmers are concerned about this, with an increasing number of farmers reporting resistance to the three groups of wormers that have been available up to now, so the introduction of Zolvix is very timely."
At the same time, the company has also launched an award-winning new drenching system designed to offer 'a superior drenching experience for both animal and operator'. The new Optiline Drencher and Optivix backpack system were developed in collaboration with drenching specialists Simcro Tech Ltd.
The Optiline Drencher has already won several design and engineering awards, including a bronze award in the 2009 NZ BEST design awards, a coveted International Forum (IF) 2010 product design award from Germany and the prestigious Bayer Innovators Award for design and engineering.
It was also a finalist in the New Zealand Agritech Innovation Awards reached the finals in three categories of the 2009 New Zealand Trade and Enterprise International Business Awards.
The Optiline drencher is coupled with a durable, light Optivix backpack that has been specially tailored to provide left or right-handed operators with the same wide range of adjustment. It also has two drench cradles - at chest and hip level - to ensure maximum comfort.
Mr Harris said: "This drencher is best appreciated during use. Contact your local Novartis Animal health representative to arrange a trial."
Metaxol contains 20 mg trimethoprim and 100 mg sulfamethoxazole per ml and can be added directly to drinking water or used in a concentrated stock.
The new product, which is part of the company's SoluStab range, replaces Methoxasol. Dechra says it is likely to be welcomed by farmers wanting to target entire flocks because of its shorter withdrawal time for broilers.
Dechra Brand Manager Emma Jennings said: "Sulfamethoxazole is a potent sulfonamide and, when combined with trimethoprim, it has a synergistic and bactericidal effect.
"Both active ingredients are rapidly absorbed and distributed widely in tissues making it a highly effective treatment.
"The shorter withdrawal time for broilers will make it an attractive treatment for farmers wanting to target entire flocks."
Metaxol is not suitable for laying hens.
In fattening pigs, Metaxol is suitable for the treatment and metaphylaxis of post-weaning diarrhoea caused by beta-haemolytic K88-positive, K99-positive or 987P Escherichia coli strains susceptible to trimethoprim-sulfamethoxazole.
It can also be used for secondary bacterial infections caused by Pasteurella multocida, Actinobacillus pleuropneumoniae, Streptococcus spp. and Haemophilus parasuis susceptible to trimethoprim-sulfamethoxazole.
In broilers, it can be used for treatment and metaphylaxis of Colibacillosis caused by Escherichia coli susceptible to trimethoprim-sulfamethoxazole or Coryza caused by Avibacterium paraga.
The recommended dosage is 0.25 ml of product per kg body weight per day for four to seven days for pigs and 0.38 ml of product per kg body weight per day for three days for chickens.
For support in calculating dosages, visit http://calculator.solustab.eu/.
Phil Kenward from Farm Vets South West in Bridgewater, Somerset has won a bottle of port from the Veterinary Benevolent Fund for submitting the best practical veterinary tip.
The tip was:
"Do not allow the owner's diagnosis of his problem to worry or influence you before you examine the animal yourself."
The competition was run to celebrate the launch of The Pocket Book of Tips For Practising Vets which can be ordered on-line from the Vetlife website to raise funds for the VBF charity.
Lydia Brown, President of the VBF, said: "This book has been a monumental effort by six mixed practice vets, to both share their experience with the profession and to provide very welcome funds for the veterinary profession's own charity, the VBF. We are currently raising money for the new Vet Helpline e-mail support service which will launch at the end of the year so we are extremely grateful to everybody concerned for all their efforts."
Procapen contains a high dose of procaine benzyl penicillin, a narrow spectrum antibiotic which targets the most important pathogens in fresh cases of mastitis in cows and is the drug of choice against benzylpenicillin-susceptible streptococci and staphlococci.
Marcus Scott, Large Animal Business Manager at Forte said: "With the widespread shortage of intramammary tubes at the moment, Procapen provides a welcome solution for many mastitis cases."
For more information, contact your local Forte Territory Manager or email: enquiries@fortehealthcare.com.
Zoetis has launched a one-dose vial of Rispoval IntraNasal, in order to offer respiratory health protection in calves as soon as possible after birth without either waiting to batch them in groups or wasting unused vaccine in multi-dose packs.
To make ready for use, the vaccine is reconstituted by mixing a powder with sterile diluent. Once mixed, the licensed shelf life is two hours. This means any that is unused in multi-dose packs must be thrown away. By stocking a combination of one- and multi-dose packs, farmers can eliminate this.
The vaccine protects against two primary viral causes of pneumonia in young calves, BRSv and Pi3v1. Surveillance of blood samples from 2,145 calves with pneumonia signs found 78% exposed to BRSv, 81% to Pi3v2. The product licence allows use from nine days of age, with onset of immunity to BRSv and Pi3v after five and 10 days respectively. The licence also specifies a duration of immunity of 12 weeks.
Zoetis vet Carolyn Hogan says that viruses are the instigator of a majority of respiratory health problems: "Early-life protection also helps reduce the threat from opportunistic secondary bacterial infections, such as Pasteurella.
"Good respiratory health is essential to ensure calves develop to achieve their lifetime potential. But it's estimated that 67% of pneumonia cases occur in calves less than three months of age3.
"Whether suckled or reared, calves that don’t grow effectively in the early weeks are unlikely to catch up later. On both dairy and beef units, proactive management of the calf living space, nutrition and disease resilience is critical to maximise lifetime productivity, which is clearly so important under today's farm business economics.
More information about the benefits of managing respiratory health in calves is available at plantoproduce.co.uk.
A new injectable antibiotic with nil-milk-withhold licensed to treat foul-in-the-foot in a single shot has been launched by Pfizer Animal Health.
Naxcel Cattle's active ingredient is ceftiofur in a patented sustained-release formulation. According to the company, one injection provides a full course of antibiotic therapy, giving seven days of therapeutic blood levels against the majority of inter-digital necrobacillosis ('foul-in-the-foot') pathogens.
Pfizer vet Dave Gilbert says the expectation is that Naxcel Cattle will make on-farm therapy easier and help improve treatment compliance and thereby first treatment success rates, compared to treatments which require repeat injections. "Having the full course in a single injection simplifies treatment protocols and eliminates a number of reasons for non-completion of treatment, such as forgetting a second or third dose, or not giving them because of apparent symptomatic recovery from the condition."
The site of injection for Naxcel Cattle is the subcutaneous area at the base of the ear (see Figures 1 & 2). Injection instructions are supplied in the product pack. Dave Gilbert suggests that provided cattle are adequately restrained during administration the injection technique is simple and straightforward. The dose rate is 1ml/30kg body weight and up to 30ml can safely be given into each site.
Figure 1. Subcutaneous administration of Naxcel Cattle at the posterior aspect of the ear where it attaches to the head (base of ear).Figure 2. Injection location for the subcutaneous administration of Naxcel Cattle at the posterior aspect of the ear where it attaches to the head (base of ear).
The MSD Animal Health Research Bursary for Veterinary Surgeons offers three awards, consisting of two ruminant bursaries and one companion animal bursary, of up to £4,000 each.
Each project should be completed within one to two years and the vet practitioner proposals will be judged by university academics to ensure independent assessment.
The companion animal research bursary will be assessed by the University of Nottingham Centre for Evidence-based Veterinary Medicine and the ruminant research bursary applications will be assessed by academic staff from the University of Bristol School of Veterinary Science.
Michelle Townley, veterinary advisor at MSD Animal Health (pictured right) said: "Our Vet Surgeon Research Bursaries have an important role to play in encouraging vet surgeons to continue to develop their research skills. New knowledge and good research skills form the life-blood of the industry so we’re keen to see proposals from both ruminant and companion animal practitioners. Being awarded a bursary has proved to be a career-changing experience for some participants so we’re keen to get as many applications as possible as part of our investment in the veterinary industry."
The deadline for entries is 30th November 2018. For more information, visit www.msdahresearchbursary.co.uk.
The company says Bovela is the only BVD vaccine available proven to provide 12 months’ protection, against both types of BVD, and after only one shot.
Cattle business manager, Robert Bakewell said: "Provided Bovela is used as recommended on the product label, we are happy to guarantee that it will prevent the birth of PI (persistently infected) calves caused by transplacental infection by the BVD virus.
"We are also encouraging farmers to seek advice and input from their vet about BVD control by offering a £50 voucher towards testing for Bovela users. All herd owners need to do is speak to their veterinary surgeon or email bvdzero.uk@boehringer.com."
At this year’s event, sessions include ‘Backyard pigs – Notifiable Diseases and Zoonosis’, and a discussion on the role of paraprofessionals in the sector led by Simon Hall, APHA’s Director for EU Exit and Trade.
Drop-in Q&A sessions, workshops offering practical advice and guidance on the revalidation process and a strong focus on the Cymorth TB programme in Wales also feature.
The conference programme includes dedicated lecture streams aimed at large animal, small animal and equine practitioners and, with more than 8,000 OVs due to revalidate their qualifications in March 2019, Improve says lecture content has been tailored to cover areas of key relevance for them.
An exhibition of products and services for OV’s runs alongside the conference.
APHA’s recently appointed Veterinary Director, Dr Andrew Soldan (pictured right), said: "Having recently taken on the role of Veterinary Director for APHA, I am very much looking forward to meeting up with our OV’s and exploring some of the key challenges facing us all, as we seek to control animal disease threats at home and from abroad."
David Babington MRCVS, Business Development Director at Improve International, said: "This conference has established itself as an annual fixture in the OV diary and it remains the only event dedicated to their needs. This year’s packed programme will again highlight the growing importance of OV’s, particularly as we look ahead to the post-Brexit era."
For more information on the Official Veterinarian Conference and Exhibition or to register visit: www.officialvet.com
Rexxolide contains 100 mg/ml of tulathromycin, which is widely used to treat BRD and SRD. It also has a single dose and low injection volume of 1 ml/40 kg BW, to make it more convenient.
Dechra says Rexxolide has an immune-modulating and anti-inflammatory action and offers equal viscosity and syringability as other products on the market1. It can be used for treatment and metaphylaxis of BRD and SRD and offers early-stage treatment for infectious pododermatitis.
Dechra’s Equine and Food Producing Animal Brand Manager, Emma Jennings said: “Launching Rexxolide into the market provides an alternative option to existing BRD, SRD and foot rot treatments for farm vets across the UK and Ireland.
"We support an integrated approach to the control of BRD, with good husbandry, early detection and correct therapy being vital tools in managing the multi-factorial condition."
Rexxolide is available in 50ml and 100ml vials. For more information visit www.dechra.co.uk.
Intervet/Schering-Plough Animal Health has launched a new cattle and sheep vaccine which it says gives vets an additional opportunity to prescribe the broadest possible protection against clostridial diseases.
Bravoxin 10 is a low dose clostridial vaccine containing antigens for protection against C. perfringens type A, C.perfringens type B, C.perfringens type C, C.perfringens type D, C.novyi type B, C.septicum, C.tetani, C.sordellii, C.haemolyticum and C.chauvoei.
Dosage volumes are 2ml for cattle and 1ml for sheep and the new vaccine can be used in animals from as young as two weeks old if the dam has not been previously vaccinated. A booster dose pre-calving or lambing will also deliver 8-12 weeks passive immunity in calves and lambs (apart from against C.haemolyticum).
Intervet/Schering-Plough Animal Health ruminant veterinary adviser Rosemary Booth MRCVS said: "Clostridial bacteria take the lives of cattle and sheep on a regular basis and are the cause of a significant proportion of the sudden livestock deaths in this country. In 2007, an independent survey of over 500 UK dairy and beef farmers revealed that half the interviewees had experienced calves or adult cattle dying for no apparent reason. The reality is that many of these losses could have been due to clostridial diseases. Farmer respondents valued the livestock loss at anywhere between £505 and £1243 per animal. Even at the lowest stock valuation, preventing the loss through broad-spectrum vaccination would pay for nearly five years of Bravoxin 10 use in a 100 cow herd.
"Now that additional clostridial pathogens such as C. sordellii and C. perfringens A have been recognised by the VLA and SAC as significant causes of deaths on both cattle and sheep farms, it makes sense to widen pathogen cover on some ruminant livestock units. Bravoxin 10 allows practitioners to prescribe the broadest possible disease protection."
The sheep industry already understands the importance of broad-spectrum vaccination against clostridial diseases, but Iain Carrington from Intake Veterinary Services based in Northumberland believes cattle producers should also upgrade their protection.
"There was a time that clostridial disease control in cattle meant vaccinating your youngstock against blackleg at turnout, or discovering dead animals and then reacting with blackleg vaccine," he said. "But over the last few years, I have seen an increased incidence of different clostridial diseases in far from typical circumstances.
"There are also a large number of cattle deaths going undiagnosed and it is likely that many are caused by clostridial species. As a result, we are now advising many of our clients to take a broader-spectrum vaccination approach to ensure adequate protection - not only of the cows themselves - but also their calves through good colostral transfer," he said.
Bravoxin 10 is a prescription-only medicine (POM-V). For further information, contact the Intervet/Schering-Plough Animal Health Veterinary Support Group on 01908 685685.
The RCVS Disciplinary Committee has suspended a Cardigan veterinary surgeon from the RCVS Register for five months, for failure to perform accurate bovine tuberculin testing and for falsely certifying the test results.
During the two-day hearing, Dewi Wyn Lewis, of Priory Veterinary Ltd, Cardigan, answered charges about inaccurate skin fold measurements and false certification relating to two visits he made as an Official Veterinarian to a farm in April 2009 to undertake tuberculin testing.
Mr Lewis accepted that he had not carried out the tuberculin tests in the way required by Animal Health (AH) - an Executive Agency of the Department for Environment, Food and Rural Affairs - and had taken short cuts to save time. However, he denied the charges, arguing that, although instructions to Official Veterinarians clearly required the use of callipers to measure the skin folds of cattle necks on Day One of testing, not using callipers and using his finger and thumb did not amount to failing to measure.
He also argued (and it was accepted by the Committee) that, regarding Day Two of testing, there was inconsistency in AH's instructions on calliper use, which in written form required using callipers for measuring every animal but in practice accepted use of callipers when a reaction could be detected by manually palpating the skin. On Day Two, Mr Lewis said, he had done what AH required: he had used callipers on the cattle he identified for closer examination.
The Committee, however, found that by failing to use callipers on the first day, as required by AH, Mr Lewis had failed to measure the skin folds of almost all of the 104 cattle. The Committee was also satisfied that, on the second day, 10-20% of the herd were not even touched by Mr Lewis and the Committee accepted the evidence of the three other witnesses present during the testing, which indicated that Mr Lewis had failed to carry out careful assessment and manual palpation of every animal.
The Committee then considered whether Mr Lewis had dishonestly signed the certificate, or had signed a false certificate which he ought to have known was inaccurate. The Committee noted that there were no previous Disciplinary findings against Mr Lewis, and was prepared to believe his assertion that, although he knew he had not carried out the tests in strict compliance with AH's instructions, he genuinely believed his methods to be at least as accurate as measuring with callipers and did not think he was doing anything wrong or dishonest. The Committee could not then be sure that Mr Lewis had realised what he was doing was dishonest. However, the Committee noted that 'false' also means 'inaccurate' and, as Mr Lewis ought to have known that as his testing methods were not adequate, he also should have known that a considerable number of measurements on the certificate were inaccurate and that the certificate itself was inaccurate.
After considering the facts of the case, the Committee concluded that Mr Lewis's actions amounted to serious professional misconduct and directed that he should be suspended from the Register for five months, after which he may return to practice. In relation to the sanction, the Committee said: "In reaching this decision it is relevant that the false certification was not dishonest and that there was professional and personal mitigation put forward on behalf of Mr Lewis. The Committee has paid regard to the fact that Mr Lewis is an experienced veterinary surgeon who is highly thought of in his local area. It does not believe that there is any likelihood that he will repeat his previous conduct."
The Committee also said it gave considerable weight to the fact that Mr Lewis had had to wait an additional three-month period for the hearing because of an earlier adjournment.
Merial is highlighting the results of an independent study published in July's Journal of Dairy Science which showed that treating acutely lame cows with the non-steroidal anti-inflammatory (NSAID) Ketofen (ketoprofen), alongside therapeutic trimming and the application of a block, resulted in a significantly better recovery rate compared to the other treatment protocols used.
In the study, Evaluation of treatments for claw horn lesions in dairy cows in a randomised controlled trial by Thomas et al1, 56% of the cows in the above treatment group were observed to be sound.
Sioned Timothy, Merial Technical Veterinary Manager (pictured right) said: "The lack of evidence to underpin a standardised approach to treating lameness in cattle has previously been highlighted2.
"This study demonstrates the value of using an NSAID as part of lameness treatment both for its welfare benefits, and also to reduce the impact of lameness on herd productivity through improved recovery rates. It also highlights the importance of implementing herd health protocols that focus on early intervention – identifying cows as soon as they become lame should be a priority for dairy farmers. With lameness cited as having a significant adverse effect on milk yield3 and cull rate in the herd, a proactive approach to lameness control is critical. Farmers should work with their vets and foot trimmers to ensure that when lame cows are identified they are treated in the most effective way.”
Sioned added: "The importance of routine mobility scoring cannot be underestimated. Clinical lameness has been shown to cause a decreased milk yield from up to four months before diagnosis 3, which can translate to a mean reduction of 357 litres per 305 day lactation. Furthermore, the impact on fertility and the long term impact on replacement is also acknowledged, with lame cows less likely to conceive and having an increased risk of conception failing."
References
Tri-Solfen contains lidocaine and bupivacaine to deliver rapid onset and prolonged local anaesthesia, adrenalin to reduce blood loss and cetrimide to lower the risk of infection.
Dechra says the gel is effective in 30 seconds, making it a practical tool to improve animal welfare via cutaneous and epilesional use.
Tri-Solfen was originally developed and launched in Australia by Medical Ethics, a company that specialises in pain management treatments for humans and animals.
According to the company, more than 100 million animals have been treated with Tri-Solfen in Australia, New Zealand and Portugal, where it is licensed for disbudding, dehorning, castration and general wound treatments in cattle, sheep, pigs and horses.
www.dechra.co.uk
Intervet/Schering-Plough Animal Health has announced the launch of PORCILIS AR-T DF, an inactivated vaccine against progressive atrophic rhinitis in piglets with a new adjuvant which the company says is associated with fewer injection site reactions.
PORCILIS AR-T DF uses DILUVAC FORTE (DF), an aqueous vitamin E-based adjuvant and will replace PORCILIS AR-T, a similar vaccine containing an oil-based adjuvant. The newly formulated vaccine is approved to reduce the clinical signs of progressive atrophic rhinitis in their offspring. Progressive atrophic rhinitis is caused by a toxin from the bacteria Pasteurella multocida affecting bone-forming cells in the snout of the young piglet.
Marc Dickie, Senior Director, Global Swine Business Unit at Intervet/Schering-Plough Animal Health said: "The innovative PORCILIS AR-T DF vaccine combines the proven efficacy of the current PORCILIS AR-T with an improved safety profile and convenience for the veterinarian that is offered by the aqueous DILUVAC FORTE adjuvant. The new vaccine also demonstrates the commitment of our company to continuously improve our vaccines, thereby offering value-added benefits to our customers."
The company has published data from its 2021 Assure Ewe subsidised testing scheme, which found that 48% of farms that submitted samples after last year’s lambing season tested positive for EAE1 caused by Chlamydia abortus.
This, Ceva says, mirrors the results from the 2020 testing initiative, demonstrating that EAE remains a significant issue on UK farms.
Katherine Timms BVetMed (Hons) MRCVS, ruminant veterinary advisor at Ceva Animal Health said: “EAE is a significant problem on UK farms, and it can be exceptionally expensive and frustrating to deal with, as infected sheep aborting and shedding have the potential to cause an abortion storm the following year.
“Any abortion outbreak should therefore be identified and managed as quickly and effectively as possible to help prevent the rest of the ewes in the flock from becoming infected.
"Vaccination and strict biosecurity provide the best protection against EAE and farmers can vaccinate their ewes from five months of age until four weeks prior to tupping, as long as the ewe is not in lamb.”
For further information, contact your local Ceva Animal Health account manager or visit www.enzooticabortion.co.uk.
Reference
The new guidelines strongly recommend an overall reduction in the use of all classes of medically important antibiotics in food-producing animals, including complete restriction of these antibiotics for growth promotion and disease prevention without diagnosis. Healthy animals should only receive antibiotics to prevent disease if it has been diagnosed in other animals in the same flock, herd, or fish population.
WHO says that where possible, sick animals should be tested to determine the most effective and prudent antibiotic to treat their specific infection. Antibiotics used in animals should be selected from those WHO has listed as being "least important" to human health, and not from those classified as "highest priority critically important", as they are often the last line, or one of a limited number of treatments available to treat serious bacterial infections in humans.
The new guidelines were informed by a systematic review published in The Lancet Planetary Health which found that interventions that restrict antibiotic use in food-producing animals reduced antibiotic-resistant bacteria in these animals by up to 39%1.
Dr Kazuaki Miyagishima, Director of the Department of Food Safety and Zoonoses at WHO said: "Scientific evidence demonstrates that overuse of antibiotics in animals can contribute to the emergence of antibiotic resistance. The volume of antibiotics used in animals is continuing to increase worldwide, driven by a growing demand for foods of animal origin, often produced through intensive animal husbandry."
Dr Tedros Adhanom Ghebreyesus, Director-General of WHO said: "A lack of effective antibiotics is as serious a security threat as a sudden and deadly disease outbreak. Strong, sustained action across all sectors is vital if we are to turn back the tide of antimicrobial resistance and keep the world safe."
Responding to the announcement, BVA Senior Vice President Gudrun Ravetz said: "We welcome the WHO continuing to tackle this serious global health issue. Their guidelines echo the guidance BVA has long been issuing on the responsible use of antimicrobials.
"We agree that the prophylactic use of antimicrobials in healthy animals to prevent disease is never a substitute for good animal husbandry and management.
"Through cross-sector working, the UK is leading the way in significantly reducing antimicrobial usage, having already achieved the UK Government usage targets set for 2020.
"Critically Important Antimicrobials use is at a very low level in the UK, and, as recent Government data shows, is continuing to decrease. It is encouraging that WHO recognises that these vital medicines are sometimes needed, under veterinary judgment and prescription, as a last resort, to prevent the further spread of disease and to protect animal and human health."
The new guidelines can be downloaded here: http://www.who.int/foodsafety/areas_work/antimicrobial-resistance/cia_guidelines/en/
The new website explains what Veterinary Specialists are, how they may be able to help, and how the referral process works. The BCVSp says it has been designed to be a useful resource which primary practices can direct their clients to if a referral is being considered.
As well as being able to search for a Specialist by location and by discipline, owners can also read some real life patient case studies following the referral, treatment journeys and outcomes of animals that have benefited from Specialist care and meet some of the Specialists via podcast links.
BCVSp Trustee Celia Marr said: "While most happy healthy animals will never need Specialist veterinary care, if they do we want their owners to know that we are here to help.
"There are many hundreds of Specialists working at the forefront of veterinary care and also those working in research, pathology and academia, helping to advance animal health and welfare, every day. We believe our new website should help to spread the word and make referral more understandable and accessible."
Visit the new website at www.yourvetspecialist.org
SPVS is leading a ground-breaking new project which aims to find out how veterinary surgeons are treating a range of clinical conditions.
Two hundred practitioners are being sought to provide details of how they address clinical conditions in three study areas: small animal, equine and farm animal, on a new website: www.howdoido.org. The findings, which will be made anonymous, will eventually form the basis of a clinical benchmarking process, which will tie in with the growing trend towards evidence-based medicine.
SPVS's objective is to understand and support how clinicians work in practice and approach particular clinical cases. The Society is working alongside Dr Mark Johnson who carried out the Confidential Enquiry into Perioperative Equine Fatalities.
SPVS Junior Vice President Jacqui Molyneux said: "This is an exciting new study which will shed a lot of light on what we as clinicians are doing in practice with the eventual aim of developing a clinical benchmarking process.
"The project however will only be worthwhile if a significant number of practitioners take part, so we're encouraging vets to visit the website and find out more. It will take no longer than ten minutes to fill in each clinical case."
The award, funded by the Economic and Social Research Council (ESRC) working in partnership with the Department of Health and the Arts and Humanities Research Council (AHRC), is part of the cross-council 'Tackling antimicrobial resistance: behaviour within and beyond the healthcare setting’ call, part of the antimicrobial resistance cross-council initiative supported by the seven research councils in partnership with other UK funders including the Medical Research Council (MRC).
The research team will be led by social scientists at the University of Exeter and includes two veterinary surgeons from the University of Bristol’s School of Veterinary Sciences, together with colleagues at the Innogen Institute of the University of Edinburgh, the British Veterinary Association and leading farm animal veterinary surgeons across the UK.
The researchers say that better, smarter, more rapid and more accessible diagnoses - driving shifts in behaviour associated with diagnostic decision making - represent a critical step to delivering more effective uses of antibiotics in animal health. But improvements in diagnostic development and their relationship to prescription and treatment requires social, governance and technical innovations.
Professor Henry Buller, project lead from the University of Exeter’s School of Geography, said: "This is an exciting opportunity to provide a current assessment of diagnostic and treatment decision practices in the livestock sectors of the UK. Novel and innovative diagnostic tools are currently in development, and our research will generate better understanding of their development as well as the marketing and regulation of these new technologies."
Dr Kristen Reyher, Senior Lecturer in Farm Animal Science, who is the lead on the project at the University of Bristol’s School of Veterinary Sciences, added: "Our research team – the AMR Force – has a track record of working closely with farmers, veterinarians, retailers and government bodies to encourage responsible use of antibiotics. We are excited to have this amazing opportunity to collaboratively generate, evaluate and analyse behaviours and strategies around animal disease diagnosis and to show how innovation in the development of diagnostic tools along with diagnostic regulation and governance can lead to more sensible use of antibiotics across farming systems.
"Working with our partners, we will identify pathways and possibilities for improved diagnostic practice and will trial new diagnostic tools on a series of farms. We are very excited to take our ideas beyond the UK as well, and will conduct pilot and capacity-building research in Tanzania and also partner with a project working in Bangladesh that is co-funded by ESRC and the Centre for Environment Fisheries and Aquaculture Science."
Professor Buller added: "Employment of new diagnostics doesn’t occur in a vacuum. Our team will evaluate the implications these innovations will have for the organisation, cost-effectiveness and efficiency of veterinary practice, as well as for veterinary training. We will identify the changes in behaviour, practice and knowledge necessary to accompany the more widespread adoption of practices that are deemed effective and will assess the regulatory and governance support necessary to encourage use of beneficial practices."
The interdisciplinary team will work alongside diagnostic tool developers and regulators, veterinary practices and professional bodies, farmers and treatment decision makers, veterinary laboratories, the food industry and government regulatory authorities to develop durable and innovative strategies for facilitating and advancing smarter approaches to the use of antibiotics in agriculture.
The work will cover the major livestock species, and will involve seeking opinions from veterinary surgeons across the country, through collaboration with the BVA.
David Barrett, Professor of Bovine Medicine, Production and Reproduction at the University of Bristol’s School of Veterinary Sciences, said: "This is a fantastic opportunity to assess the adaptability and responsiveness of the different animal production sectors - poultry, pigs and cattle - along with a variety of veterinary structures to the trialled innovations in diagnosis and diagnostics, and will determine the likely benefits of these innovations for prescription practice, for animal health and for sustainable livestock production."
Photo: University of Bristol
The Dairy Vet of the Year award, which is organised by the British Dairying Magazine and sponsored by Krka UK Ltd, recognises a veterinary surgeon for going the extra mile in helping to create a more positive, forward-thinking dairy industry.
In addition to her work as a farm vet, Sarah is also Technical Director at the TB Advisory Service (TBAS), which involves her overseeing and delivering training for new advisors, chairing technical board meetings and delivering farmer meetings across the country. She also provides bespoke advice to farmers in High Risk and Edge Areas of England, and is known for her compassion and understanding for those suffering a TB breakdown.
She is also a member of the TB Eradication and Advisory Group (TBEAG) for England, which advises government policy makers on all aspects of TB control in England.
Lindsay Heasman, Project Manager at TBAS, said: “Sarah is an authority on TB and understands the responsibility that comes with this role. She uses her position for good at all times and is prepared to make statements that are not always universally popular. By standing by her beliefs and dispelling misconceptions, she has won the respect of farmers across the country. Her dedication has, at times, come at personal cost, but her passion for eradicating bTB and support for farmers in achieving this goal never wavers.”
Sarah said: “I am just a farm vet doing the same job every farm vet does daily across the country. Through necessity, seeing my clients being devastated by TB breakdowns every day, I felt passionate about doing something about it. TBAS, my colleagues I am lucky to work with, and TBEAG have given me the platform to do this. I am very humbled that the judges though me worthy of the Award amongst the other hard-working vets."
Photo: Giles Brandreth, Charlotte Read, Sarah Tomlinson and Sean Sparling
Flimabend is diluted into water and replaces the flock’s drinking water for a set period during the day.
The new 20g pack includes a post-prescription leaflet to help veterinary surgeons support clients in calculating the correct dose, based on the bodyweight of their flock. It also includes a measuring scoop to ensure accurate administration.
Flimabend is effective against the three key intestinal worms affecting chickens – Ascaridia (roundworm); Capillaria (hairworm) and Heterakis gallinarum, which can be a vector for Blackhead disease. No egg withdrawal period is required.
Charlotte Read, Krka's Key Account Manager – Farm said: “Poultry-rearing is on the increase in the UK, both at a commercial level and among the public. Recent figures suggest that more than one million UK households keep chickens, with the majority of domestic flocks comprising five laying hens and a cockerel1.
"A regular worming routine is, of course, essential for optimal flock health and ensuring ease of use in a worming product is the most effective way of ensuring compliance, especially among those keeping backyard chickens.
“As one of the first water-based worming products available for small flocks, Flimabend now offers an innovative presentation of Flubendazole which we believe offers a new level of convenience and flexibility.”
Krka is currently offering virtual ‘lunch and learns’ on the worming of backyard chickens. Contact your Krka Account Manager for more details.
CEVA Animal Health has launched a double-sized version of Cyclo Spray, the company's chlorotetracycline-based treatment for the clinical symptoms of foot rot in sheep and digital dermatitis in cattle.
CEVA says that Cyclo Spray's superior spray performance makes it very cost-effective: the aerosol generates a narrow, condensed spray with limited dispersion for accurate application and minimal drip. The spray adheres cleanly and dries fast on the treatment area, to ensure that the antimicrobial has maximum efficacy within the shortest possible spray time.
CEVA adds that each spray of Cyclo Spray covers the skin with a concentration of chlorotetracycline that is thousands of times greater than is actually required to kill the causative bacteria.
The original size can is also available if required.
For further information contact CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG.
Fort Dodge Animal Health has announced that its Zulvac 8 Ovis® Bluetongue sheep vaccine is now licensed and available in the UK. The company believes that the product will provide significant benefits to sheep farmers.
Zulvac 8 Ovis® is an inactivated adjuvanted vaccine for the active immunisation of sheep by subcutaneous injection against Bluetongue Serotype 8. It also provides a reduction in viraemia. Administration is a two x 2 ml dose primary course in year one but only a single shot booster in the second year.
The use of Zulvac 8 Ovis as a booster for animals previously vaccinated with a primary course from other manufacturers is in line with Defra (2009) guidance: 'No problems are anticipated with re-vaccinating animals which have already received a primary course of vaccination with a different vaccine 1'.
The first dose can be administered from one month of age and Zulvac 8 Ovis® is proven for use in pregnant sheep. The onset of immunity is provided 25 days after the second dose.
Fort Dodge says Zulvac provides cost savings to farmers through its pricing strategy. While the price for the two dose primary course is competitive with alternative vaccines, for animals which were vaccinated last year and require only a single shot booster, the cost will be half that of competitive offerings, providing a significant incentive to farmers to vaccinate.
The vaccine is supported by a specific Zulvac Ovis fixed 2ml dose applicator with Sterimatic needle protector and cleaning system which aids administration and hygiene and is sold separately.
David Bartram MRCVS, Veterinary Technical Manager at Fort Dodge, said: "Sheep farmers have been waiting for a Bluetongue vaccine which offers a cost effective solution to vaccination - particularly for animals which received their primary course last year and are simply in need of a booster. We expect the fact that it's licensed for use in pregnant sheep to also prove attractive.
"Zulvac 8 Ovis® is the latest addition to Fort Dodge's Zulvac range for both cows and sheep. It is already used in Europe and has helped protect millions of animals."
Located in the South East of England, the centre is part of the new School of Veterinary Medicine at the University of Surrey, and one of the UK's largest veterinary pathology centres, offering high-containment post-mortem examination facilities and histopathology.
The centre is staffed by a team of board-certified veterinary pathologists, veterinary investigation officers and technicians, with expertise in farm-animal, equine, exotic and small-animal pathology.
The new building centres on a large containment level 2 post-mortem examination room with high ceilings, natural lighting, post-mortem examination tables, biological safety cabinets and integrated cold rooms, all served by a powerful winch system which means that post-mortem examinations can be performed on a wide range of species. A viewing gallery overlooks the suite and post-mortem examinations can be recorded and streamed for training purposes.
Professor Roberto La Ragione, Director of the Veterinary Pathology Centre, said: "Veterinary pathology is a growing discipline and its importance has been highlighted in recent disease outbreaks and the important role veterinary pathologists make in drug development. Helping the farming community to be more effective, sustainable and innovative, the Centre will work with partners, businesses and researchers to address some of the unique challenges faced by the veterinary and scientific community.
"It is the close relationships with our external clinical and scientific partners that enables us to be innovative in our approach to education and training here at the Surrey. An example of the latter is the use of digital pathology in teaching, research and diagnostics, which was the subject of discussion at the recent launch of the Veterinary Health Innovation Engine (vHive).
"Together with our partners such as the National Physical Laboratory and the 5G Innovation centre, the Centre is at the forefront of the digitalisation of pathology and innovative big data management.
"The Centre offers the opportunity to inspire the next generation of veterinary pathologists and complements the centres of excellence that already exist in other vet schools and research institutes."